<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03217786</url>
  </required_header>
  <id_info>
    <org_study_id>0868</org_study_id>
    <nct_id>NCT03217786</nct_id>
  </id_info>
  <brief_title>Early Post Transplant Cardiac Allograft Vasculopathy</brief_title>
  <acronym>ECAV</acronym>
  <official_title>Early Post Transplant Cardiac Allograft Vasculopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Toronto General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart transplantation is an effective life-saving treatment for patients with end-stage heart&#xD;
      disease. After a transplant, the new heart may develop narrowing in the arteries, causing&#xD;
      heart failure, heart attacks and abnormal heart rhythms. This condition is known as cardiac&#xD;
      allograft vasculopathy (CAV). The disease is very common, affecting almost a third of heart&#xD;
      transplant patients by 5 years after transplant. CAV is a serious problem that causes the new&#xD;
      heart to fail and is one of the main causes of death after transplant. Early detection of CAV&#xD;
      is important as treatment options are poor once the disease is established. Currently,&#xD;
      available techniques to evaluate CAV are limited by poor ability to detect disease early. The&#xD;
      current tests usually focus on the large heart arteries and do not examine the smaller&#xD;
      arteries that are also affected.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to determine whether early abnormalities of the heart arteries&#xD;
      after heart transplantation can predict the development of CAV. We will use a combination of&#xD;
      sophisticated imaging tools to examine in detail the early changes that occur in the arteries&#xD;
      of a new heart. Heart transplant patients from the University of Ottawa Heart Institute and&#xD;
      Toronto General Hospital will undergo a series of tests at 3 and 12 months after transplant.&#xD;
      Statistical analyses will determine whether results from the above tests at 3 months predict&#xD;
      the development of early CAV at 12 months after a heart transplant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2018</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CAV on invasive coronary studies</measure>
    <time_frame>3 months and 1-year post-transplant.</time_frame>
    <description>Changes in coronary intima on IVUS and OCT and invasive coronary flow</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EMBx</measure>
    <time_frame>3 months post-transplant</time_frame>
    <description>Microvascular disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PET</measure>
    <time_frame>3 months post-transplant</time_frame>
    <description>Myocardial blood flow quantification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>3 months post-transplant</time_frame>
    <description>Serum biomarker panel</description>
  </secondary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cardiac Allograft Vasculopathy</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Specimens will be assessed for potential CAV biomarkers.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This prospective longitudinal study will involve 2 Canadian adult heart transplant&#xD;
        programs: University of Ottawa Heart Institute (UOHI, Ottawa) and University Health&#xD;
        Network-Toronto General Hospital (UHN-TGH, Toronto).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Heart transplant &lt;3 months.&#xD;
&#xD;
          2. Age ≥18 years.&#xD;
&#xD;
          3. Able and willing to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindications to dipyridamole.&#xD;
&#xD;
          2. Contraindications to aminophylline.&#xD;
&#xD;
          3. Contraindications to nitroglycerin.&#xD;
&#xD;
          4. Contraindications to iodinated contrast.&#xD;
&#xD;
          5. Acute allograft rejection ≤1 month.&#xD;
&#xD;
          6. Uncontrolled heart failure or myocardial infarction ≤7 days.&#xD;
&#xD;
          7. Estimated glomerular filtration rate ≤30 mL/min.&#xD;
&#xD;
          8. Combined solid organ transplantation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon Chih, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sharon Chih, MD, PhD</last_name>
    <phone>613-696-7000</phone>
    <phone_ext>14869</phone_ext>
    <email>schih@ottawaheart.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aun Yeong Chong, MD</last_name>
    <phone>613-696-7000</phone>
    <phone_ext>14869</phone_ext>
    <email>achong@ottawaheart.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Chih</last_name>
      <phone>613-696-7327</phone>
      <phone_ext>67339</phone_ext>
      <email>schih@ottawaheart.ca</email>
    </contact>
    <contact_backup>
      <last_name>Aun Yeung Chong</last_name>
      <phone>613-696-7339</phone>
      <phone_ext>67339</phone_ext>
      <email>achong@ottawaheart.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Sharon Chih</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 11, 2017</study_first_submitted>
  <study_first_submitted_qc>July 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Macrovascular Disease</keyword>
  <keyword>Microvascular Coronary Artery Disease</keyword>
  <keyword>Cardiac Transplant Rejection</keyword>
  <keyword>Transplant; Failure, Heart</keyword>
  <keyword>Intravascular ultrasound (IVUS)</keyword>
  <keyword>Optical Coherence Tomography</keyword>
  <keyword>Index of Microcirculatory Resistance</keyword>
  <keyword>Fractional Flow Reserve</keyword>
  <keyword>Coronary Flow Reserve</keyword>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>Endomyocardial Biopsies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

